Retinoblastoma Aqueous Humor Liquid Biopsy Repository

Request Access

Demographics (2)

Disease Events (9)

  • AFFECTION_STATUS - Affection status for unilateral or bilateral retinoblastoma (phv00526043.v1.p1)
  • AGE_Dx - Age at Diagnosis (phv00526045.v1.p1)
  • GERMLINE RB1 MTN - RB1 mutation detected in the peripheral blood, germline disease (Y/N) (phv00526044.v1.p1)
  • HIGH_RISK_PATHOLOGIC_FEATURES - At enucleation, high risk features: massive choroidal invasion, pre-laminar invasion, post-laminar invasion, extra-scleral invision, anterior segment invasion (phv00526058.v1.p1)
  • IS_TUMOR - Tumor information from aqueous humor liquid biopsy or tumor from enucleated eye (phv00526052.v1.p1)
  • METASTATIC_DISEASE - The patient developed metastatic disease? Y/N (phv00526059.v1.p1)
  • TUMOR_PRIMARY_TREATMENT - Type of tumor treatment for sample (systemic chemotherapy, intra-arterial chemotherapy, enucleation) (phv00526055.v1.p1)
  • TUMOR_STAGE_AJCC - Tumor stage of sample based on AJCC RB classification as Mallipatna, A. C. et al. in AJCC Cancer Staging Manual, 8th ed. (eds Mahul B. Amin et al.) Ch. 68, 819-831 (Springer, 2017). (phv00526054.v1.p1)
  • TUMOR_STAGE_IIRC - Tumor stage of sample based on IIRC RB classification as A-E as in A. Linn Murphree. Intraocular Retinoblastoma: the case for a new group classification. Ophthalmol Clin North Am. 2005 Mar; 18(1):41-53. PMID: 15763190 (phv00526053.v1.p1)

General Health (1)

Race and Ethnicity (1)

Other (11)

  • ANALYTE_TYPE - Analyte Type (DNA) (phv00526051.v1.p1)
  • BODY_SITE - Body site where sample was collected (right or left eye) (phv00526050.v1.p1)
  • CONSENT - Consent group as determined by DAC (phv00526037.v1.p1)
  • Ethnicity - Ethnicity (phv00526048.v1.p1)
  • Follow_Up - Follow up as of November 2022 in months (phv00526046.v1.p1)
  • SAMPLE_ID - Sample ID (phv00526049.v1.p1)
  • SAMPLE_ID - Sample ID (phv00526040.v1.p1)
  • SUBJECT_ID - Subject ID (phv00526041.v1.p1)
  • SUBJECT_ID - Subject ID (phv00526036.v1.p1)
  • SUBJECT_ID - Subject ID (phv00526039.v1.p1)
  • TIMING_SAMPLE - Timing of sample extraction during therapy: Diagnosis (DX), end of course of systemic chemotherapy (END CEV), end of course of Intra-arterial chemotherapy (END IAC), intravitreal injections (listed in order as IvitC-A, B, C), at the time of a recurrence, at the time of primary enucleation (PE) or secondary enucleation (ES), At the time of Avastin injection (labelled in order A, B, C) (phv00526056.v1.p1)